tumour and cardiology
Conditions
Interventions
NDM2 chemotherapy:NDM2 chemotherapy
DM2 chemotherapy:DM2 chemotherapy
chemotherapy plus dexrazoxane:chemotherapy plus dexrazoxane
Sponsors
Fourth Hospital of Hebei Medical University
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: Inclusion criteria: histologically confirmed diagnosis of early breast cancer; candidate for treatment with an epirubicin-based adjuvant chemotherapy regimen according to international standardized protocols; completely resected unilateral breast cancer; blood pressure within the normal range (=50%; normal hepatic and renal function (bilirubin <=1.5 mg/dl, creatinine <=2.0 mg/dl); normal sinus rhythm; no concomitant medications such as angiotensin converting enzyme inhibitor (ACEI), B receptor blocker (B-block), Calcium antagonists (CCB) or oxidative stress parameters such as Vc, VE.
Exclusion criteria
Exclusion criteria: Acute DM2 complications; severe chronic DM2 complications; acute stress reactions such as external injury, surgery or infection one week before blood collection; history of cardiac disease; hypertension; hypo/hyperthyroidism; hemolytic, hepatic, and renal diseases; present or past history of coronary artery disease, symptoms of congestive heart failure, established structural heart disease such as cardiomyopathy or valvular disease; history of chemotherapy or radiotherapy; ST-segment or T-wave changes specifically for myocardial ischemia, Q waves, and incidental left bundle branch block on electrocardiography.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Heart rate variability index;Echocardiographic index;SOD and MDA; | — |
Countries
China
Contacts
Public ContactFangyi Sun
Outcome results
None listed